Respiratory manifestations of systemic lupus erythematosus: old and new concepts

Best Practice and Research: Clinical Rheumatology

Volumn 23, Issue 4, 2009, Pages 469-480

  Pego Reigosa, José María ^a   Medeiros, Dina A ^b   Isenberg, David A ^c  

^a UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^b INSTITUTO PORTUGUÊS DE REUMATOLOGIA   (Portugal)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

cancer; lung; pleuropulmonary involvement; pulmonary damage; pulmonary vascular involvement; respiratory infection; respiratory mortality; systemic lupus erythematosus

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DIGOXIN; DIURETIC AGENT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; ISONIAZID; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PNEUMOCOCCUS VACCINE; PREDNISONE; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; THEOPHYLLINE; WARFARIN;

ADULT RESPIRATORY DISTRESS SYNDROME; BRONCHOSCOPY; CANCER RISK; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DIAGNOSTIC TEST; DRUG MEGADOSE; EARLY DIAGNOSIS; EXPERIENCE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HYPOXEMIA; INFLUENZA; INTERSTITIAL LUNG DISEASE; LUNG ANGIOGRAPHY; LUNG BIOPSY; LUNG CANCER; LUNG DISEASE; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG INFECTION; LUNG LAVAGE; LUNG SARCOIDOSIS; MORTALITY; NONHODGKIN LYMPHOMA; PATIENT CARE; PLASMAPHERESIS; PLEURA BIOPSY; PLEURISY; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; SHRINKING LUNG SYNDROME; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX RADIOGRAPHY; TUBERCULOSIS;

HUMANS; LUNG DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; PLEURAL DISEASES;

EID: 67649803459     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2009.01.002     Document Type: Review

References (69)

1. Weinrib L., Sharma O.P., and Quismorio Jr. F.P. A long-term study of interstitial lung disease in systemic lupus erythematosus. Semin Arthritis Rheum 20 (1990) 48-56
2. Haupt H.M., Moore G.W., and Hutchins G.M. The lung in systemic lupus erythematosus. Analysis of the pathologic changes in 120 patients. Am J Med 71 (1981) 791-798
3. Matthay R.A., Schwarz M.I., Petty T.L., et al. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore) 54 (1975) 397-409
4. Travis W.D., King T.E., and Bateman E.D. ATS/ERS Consensus statement of idiopathic interstitial pneumonias. Am J Respir Crit Care Med 265 (2002) 277-304
5. Tansey D., Wells A.U., Colby T.V., et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 44 (2004) 585-596
6. Cheema G.S., and Quismorio Jr. F.P. Interstitial lung disease in systemic lupus erythematosus. Curr Opin Pulm Med 6 (2000) 424-429
7. Inoue T., Kanayama Y., Ohe A., et al. Immunopathologic studies of pneumonitis in systemic lupus erythematosus. Ann Intern Med 91 (1979) 30-34
8. Good Jr. J.T., King T.E., Antony V.B., and Sahn S.A. Lupus pleuritis. Clinical features and pleural fluid characteristics with special reference to pleural fluid antinuclear antibodies. Chest 84 (1983) 714-718
9. Pines A., Kaplinsky N., Olchovsky D., et al. Pleuro-pulmonary manifestations of systemic lupus erythematosus: clinical features of its subgroups. Prognostic and therapeutic implications. Chest 88 (1985) 129-135
10. Pertschuk L.P., Moccia L.F., Rosen Y., et al. Acute pulmonary complications in systemic lupus erythematosus. Immunofluorescence and light microscopic study. Am J Clin Pathol 68 (1977) 553-557
11. Zamora M., Warner M.L., Tuder R., and Schwarz M.I. Diffuse alveolar hemorrhage and systemic lupus erythematosus: clinical presentation, histology, survival, and outcome. Medicine 76 (1997) 192-202
12. Santos-Ocampo A.S., Mandell B.F., and Fessler B.J. Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. Chest 118 (2000) 1083-1090
13. Erickson R.W., Franklin W.A., and Emlen W. Treatment of hemorrhagic lupus pneumonitis with plasmapheresis. Semin Arthritis Rheum 24 (1994) 114-123
14. Rojas-Serrano J., Pedroza J., Regalado J., et al. High prevalence of infections in patients with systemic lupus erythematosus and pulmonary haemorrhage. Lupus 17 (2008) 295-299
15. Hatano S., and Strasser T. World Health Organization 1975 primary pulmonary hypertension (1975), WHO, Geneve
16. Pan T.L., Thumboo J., and Boey M.L. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 9 (2000) 338-342
17. Shen J.Y., Chen S.L., Wu Y.X., et al. Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int 18 (1999) 147-151
18. Kasparian A., Floros A., Gialafos E., et al. Raynaud's phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus. Lupus 16 (2007) 505-508
19. Fedullo P.F., Auger W.R., Kerr K.M., and Rubin L.J. Chronic thromboembolic pulmonary hypertension. N Engl J Med 345 (2001) 1465-1472
20. Galiè N., Torbicki A., Barst R., et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J 25 (2004) 2243-2278
21. Fayemi A.O. Pulmonary vascular disease in systemic lupus erythematosus. Am J Clin Pathol 65 (1976) 284-290
22. Quismorio Jr. F.P., Sharma O., Koss M., et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 13 (1984) 349-359
23. Chung S.M., Lee C.K., Lee E.Y., et al. Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol 25 (2006) 866-872
24. Robbins I.M., Gaine S.P., Schilz R., et al. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 117 (2000) 14-18
25. Mok M.Y., Tsang P.L., Lam Y.M., et al. Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension. Lupus 16 (2007) 279-285
26. Barst R.J., Langleben D., Frost A., et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169 (2004) 441-447
27. Wilkins M.R., Paul G.A., Strange J.W., et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 171 (2005) 1292-1297
28. González-Lopez L., Cardona-Muñoz E.G., Celis A., et al. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. Lupus 13 (2004) 105-112
29. Jais X., Launay D., Yaici A., et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension. A retrospective analysis of twenty-three cases. Arthritis Rheum 58 (2008) 521-531
30. Abramson S.B., Dobro J., Eberle M.A., et al. Acute reversible hypoxemia in systemic lupus erythematosus. Ann Intern Med 114 (1991) 941-947
31. Belmont H.M., Buyon J., Giorno R., and Abramson S. Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis Rheum 37 (1994) 376-383
32. Gladman D.D., and Urowitz M.B. Venous syndromes and pulmonary embolism in systemic lupus erythematosus. Ann Rheum Dis 39 (1980) 340-343
33. Love P.E., and Santoro S.A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 112 (1990) 682-698
34. Asherson R.A., Higenbottam T.W., Dinh Xuan A.T., et al. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 17 (1990) 1292-1298
35. Lim W., Crowther M.A., and Eikelboom J.W. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 295 (2006) 1050-1057
36. Hoffbrand B.I., and Beck E.R. 'Unexplained' dyspnoea and shrinking lungs in systemic lupus erythematosus. BMJ 1 (1965) 1273-1277
37. Bertoli A.M., Vila L.M., Apte M., et al. Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage. Lupus 16 (2007) 410-417
38. Traynor A.E., Corbridge T.C., Eagan A.E., et al. Prevalence and reversibility of pulmonary dysfunction in refractory systemic lupus: improvement correlates with disease remission following hematopoietic stem cell transplantation. Chest 127 (2005) 1680-1689
39. Toya S.P., and Tzelepis G.E. Association of the Shrinking Lung Syndrome in Systemic Lupus Erythematosus with Pleurisy: A Systematic Review. Semin Arthritis Rheum (2008 Jun 26) [Epub ahead of print]
40. Gibson C.J., Edmonds J.P., and Hughes G.R. Diaphragm function and lung involvement in systemic lupus erythematosus. Am J Med 63 (1977) 926-932
41. Martens J., Demedts M., Vanmeenen M.T., and Dequeker J. Respiratory muscle dysfunction in systemic lupus erythematosus. Chest 84 (1983) 170-175
42. Laroche C.M., Mulvey D.A., Hawkins P.N., et al. Diaphragm strength in the shrinking lung syndrome of systemic lupus erythematosus. Q J Med 71 (1989) 429-439
43. Van Veen S., Peeters A.J., Sterk P.J., and Breedveld F.C. The 'shrinking lung syndrome' in SLE, treatment with theophylline. Clin Rheumatol 12 (1993) 462-465
44. Muñoz-Rodríguez F.J., Font J., Badia J.R., et al. Shrinking lungs syndrome in systemic lupus erythematosus: improvement with inhaled beta-agonist therapy. Lupus 6 (1997) 412-414
45. Langford C.A., and Waes C. Upper airway obstruction in the rheumatic diseases: life-threatening complications of autoimmune disease. Rheum Dis Clin North Am 23 (1997) 345-363
46. Teitel A.D., MacKenzie C.R., Stern R., and Paget S.A. Laryngeal involvement in systemic lupus erythematosus. Semin Arthritis Rheum 22 (1992) 203-214
47. Thong B.Y., Thumboo J., Howe H.S., and Feng P.H. Life-threatening angioedema in systemic lupus erythematosus. Lupus 10 (2001) 304-308
48. Fenlon H.M., Doran M., Sant S.M., and Breatnach E. High-resolution chest CT in systemic lupus erythematosus. AJR Am J Roentgenol 166 (1996) 301-307
49. Andonopoulos A.P., Constantopoulos S.H., Galanopoulou V., et al. Pulmonary function of nonsmoking patients with systemic lupus erythematosus. Chest 94 (1988) 312-315
50. Keane M.P., and Lynch III. Pleuropulmonary manifestations of systemic lupus erythematosus. Thorax 55 (2000) 159-166
51. Andonopoulos A.P. Adult respiratory distress syndrome: an unrecognized premortem event in systemic lupus erythematosus. Br J Rheumatol 30 (1991) 346-348
52. Kim W.U., Kim S.I., Yoo W.H., et al. Adult respiratory distress syndrome in systemic lupus erythematosus: causes and prognostic factors: a single center, retrospective study. Lupus 8 (1999) 552-557
53. Begum S., Li C., Wedderburn L.R., et al. Concurrence of sarcoidosis and systemic lupus erythematosus in three patients. Clin Exp Rheumatol 20 (2002) 549-552
54. Hunter T., Arnott J.E., and McCarthy D.S. Features of systemic lupus erythematosus and sarcoidosis occurring together. Arthritis Rheum 23 (1980) 364-366
55. Malik S.W., Myers J.L., DeRemee R.A., and Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 154 (1996) 1851-1856
56. Lateef O., Shakoor N., and Balk R.A. Methotrexate pulmonary toxicity. Expert Opin Drug Saf 4 (2005) 723-730
57. Cronstein B.N. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 39 (1996) 1951-1960
58. Cooper Jr. J.A., White D.A., and Matthay R.A. Drug-induced pulmonary disease. Part 1: cytotoxic drugs. Am Rev Respir Dis 133 (1986) 321-340
59. Zandman-Goddard G., and Shoenfeld Y. Infections and SLE. Autoimmunity 38 (2005) 473-485
60. Bernatsky S., Boivin J.F., Joseph L., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 54 (2006) 2550-2557
61. Kinder B.W., Freemer M.M., King Jr. T.E., et al. Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus. Arthritis Rheum 56 (2007) 2679-2686
62. Fessler B.J. Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis. Best Practice Res Clin Rheumatol 16 (2002) 281-291
63. Petri M. Infection in systemic lupus erythematosus. Rheum Dis Clin North Am 24 (1998) 423-456
64. O'Neill S.G., and Isenberg D.A. Immunizing patients with systemic lupus erythematosus: a review of effectiveness and safety. Lupus 15 (2006) 778-783
65. Li J., Huang X.M., Fang W.G., et al. Pneumocystis carinii in patients with connective tissue disease. J Clin Rheumatol 12 (2006) 114-117
66. Bin J., Bernatsky S., Gordon C., et al. Lung cancer in systemic lupus erythematosus. Lung Cancer 56 (2007) 303-306
67. Bernatsky S., Joseph L., Boivin J.F., et al. The relationship between cancer and medication exposures in systemic lupus erythematosus: a case-cohort study. Ann Rheum Dis 67 (2008) 74-79
68. Gladman D., Ginzler E., Goldsmith C., et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 39 (1996) 363-369
69. Stoll T., Seifert B., and Isenberg D.A. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 35 (1996) 248-254